Serogroup B meningococcal vaccines-an unfinished story ,
, Lancet Infect Dis, vol.10, pp.112-136, 2010.
From tailor-386 made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal 387 meningococcal B outbreak, Lancet Infect Dis, vol.11, pp.455-63, 2011. ,
Outer-membrane-vesicle vaccines: old but not forgotten, Lancet Infect Dis, vol.389, pp.421-423, 2011. ,
DOI : 10.1016/s1473-3099(11)70096-2
Predicted strain 391 coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and 392 quantitative assessment, Lancet Infect Dis, vol.13, pp.416-441, 2013. ,
MATS: Global coverage estimates for 4CMenB, a novel 394 multicomponent meningococcal B vaccine, Vaccine, vol.33, pp.2629-2665, 2015. ,
,
Functional 407 and specific antibody responses in adult volunteers in new zealand who were given one of 408 two different meningococcal serogroup B outer membrane vesicle vaccines, Clin Vaccine, vol.409 ,
, Immunol, vol.14, pp.830-838, 2007.
Meningococcal 411 carriage during a clonal meningococcal B outbreak in France, Eur J Clin Microbiol Infect Dis, vol.412, pp.1451-1460, 2013. ,
, , p.414
, MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage
, Vaccine, vol.31, pp.4416-4436, 2013.
Evolution of 417 immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer 418 membrane vesicle vaccine MenBvac, Vaccine, vol.30, pp.5059-62, 2012. ,
Serum bactericidal antibody 420 assays -The role of complement in infection and immunity, Vaccine, vol.33, pp.4414-4435, 2015. ,
Meningococcal surrogates of protection--serum 422 bactericidal antibody activity, Vaccine, vol.23, pp.2222-2229, 2005. ,
mlstdbNet -distributed multi-locus sequence typing 424 (MLST) databases, BMC Bioinformatics, vol.5, p.86, 2004. ,
Persistence of 426 specific bactericidal antibodies at 5 years of age after vaccination against serogroup B 427 meningococcus in infancy and at 40 months, CMAJ, vol.187, pp.215-238, 2015. ,
,
,
, Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a 433 randomized controlled trial in Chile, Jama, vol.281, pp.1520-1527, 1999.
The concept 435 of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal 436 disease, Vaccine, vol.23, pp.2202-2207, 2005. ,
Safety and 438 immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy 439 adults: beginning of epidemic control, Vaccine, vol.24, pp.1395-400, 2006. ,
, The New, p.441
, Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating 442 epidemic, N Z Med J, vol.117, p.1015, 2004.
Expression of an 444 inaccessible P1.7 subtype epitope on meningococcal class 1 proteins, J Med Microbiol, vol.445, pp.23-31, 1993. ,
,